Medscape is available in 5 Language Editions – Choose your Edition here.


Iatrogenic Cushing Syndrome Treatment & Management

  • Author: Ha Cam Thuy Nguyen, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
Updated: Jul 20, 2016

Medical Care

The treatment for exogenous Cushing syndrome is gradual withdrawal of the causative drug, with the aim of discontinuing the causative drug if possible. An individual with HPA-axis suppression cannot increase steroid production appropriately during a medical illness or other stress and should receive stress dose steroids to avoid adrenal crisis.[27]

See Glucocorticoid Therapy and Cushing Syndrome.

Contributor Information and Disclosures

Ha Cam Thuy Nguyen, MD Fellow, Department of Endocrinology, University of Pittsburgh Medical Center

Ha Cam Thuy Nguyen, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Medical Association, Endocrine Society

Disclosure: Nothing to disclose.


Catherine Anastasopoulou, MD, PhD, FACE Assistant Professor of Medicine, Jefferson Medical College of Thomas Jefferson University; Attending Endocrinologist, Department of Medicine, Albert Einstein Medical Center

Catherine Anastasopoulou, MD, PhD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American Society for Bone and Mineral Research, Endocrine Society, Philadelphia Endocrine Society, National Osteoporosis Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Romesh Khardori, MD, PhD, FACP Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.


Gail K Adler, MD, PhD, Associate Professor of Medicine, Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School.

Disclosure: Nothing to disclose.

Susanna L Dipp, MD Fellow, Department of Medicine, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School

Disclosure: Nothing to disclose

Don S Schalch, MD Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics

Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society

Disclosure: Nothing to disclose

  1. Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology. 12th ed. Elsevier Health Sciences; May 12, 2011. 488-491.

  2. Meduri GU, Muthiah MP, Carratu P, Eltorky M, Chrousos GP. Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation. 2005. 12(6):321-38. [Medline].

  3. Christ-Crain M, Kola B, Lolli F, Fekete C, Seboek D, Wittmann G, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J. 2008 Jun. 22(6):1672-83. [Medline].

  4. Jonat C, Rahmsdorf HJ, Park KK, Cato AC, Gebel S, Ponta H, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell. 1990 Sep 21. 62(6):1189-204. [Medline].

  5. Liapi C, Chrousos GP. Glucocorticoids. Jaffe SJ, Aranda JV, eds. Therapeutic Principles in Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1992. 466-475.

  6. Tuel SM, Meythaler JM, Cross LL. Cushing's syndrome from epidural methylprednisolone. Pain. 1990 Jan. 40(1):81-4. [Medline].

  7. Matos AC, Srirangalingam U, Barry T, Grossman AB. Cushing's syndrome with low levels of serum cortisol: the role of inhaled steroids. Clin Med. 2011 Aug. 11(4):404-5. [Medline].

  8. Dutta D, Shivaprasad KS, Ghosh S, Mukhopadhyay S, Chowdhury S. Iatrogenic Cushing's syndrome following short-term intranasal steroid use. J Clin Res Pediatr Endocrinol. 2012 Sep. 4(3):157-9. [Medline]. [Full Text].

  9. Gen R, Akbay E, Sezer K. Cushing syndrome caused by topical corticosteroid: a case report. Am J Med Sci. 2007 Mar. 333(3):173-4. [Medline].

  10. Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN. Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother. 2004 Jan. 38(1):46-9. [Medline].

  11. Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA. Iatrogenic Cushing's syndrome with osteoporosis and secondary adrenal failure in human immunodeficiency virus-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases. J Clin Endocrinol Metab. 2005 Jul. 90(7):4394-8. [Medline].

  12. Kedem E, Shahar E, Hassoun G, Pollack S. Iatrogenic Cushing's syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient. J Asthma. 2010 Sep. 47(7):830-1. [Medline].

  13. Celik O, Niyazoglu M, Soylu H, Kadioglu P. Iatrogenic Cushing's syndrome with inhaled steroid plus antidepressant drugs. Multidiscip Respir Med. 2012 Aug 29. 7(1):26. [Medline]. [Full Text].

  14. Duman AK, Fulco PP. Adrenal Insufficiency With Voriconazole and Inhaled/Intranasal Corticosteroids: Case Report and Systematic Review. J Pharm Pract. 2016 May 4. [Medline].

  15. Epperla N, McKiernan F. Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone. Springerplus. 2015. 4:455. [Medline]. [Full Text].

  16. Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997 Aug 11-25. 157(15):1651-6. [Medline].

  17. Krapf R. Development of Cushing's syndrome after use of a herbal remedy. Lancet. 2002 Dec 7. 360(9348):1884. [Medline].

  18. Abuchaibe C, Akhtar ON. SAT-0776:Exogenous Cushing's Syndrome after Use of OTC Joint Supplement. Adrenal Case Reports 1 - CAH and Adrenal Insufficiency. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago. Available at Accessed: 4/2/15.

  19. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev. 1998 Oct. 19(5):647-72. [Medline].

  20. Findling JW, Doppman JL. Biochemical and radiologic diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994 Sep. 23(3):511-37. [Medline].

  21. Anastasopoulou C. Pseudo-Cushing Syndrome. Medscape Drugs & Diseases. Available at Accessed: 4/3/15.

  22. Eddy RL, Jones AL, Gilliland PF, Ibarra JD Jr, Thompson JQ, MacMurry JF Jr. Cushing's syndrome: a prospective study of diagnostic methods. Am J Med. 1973 Nov. 55(5):621-30. [Medline].

  23. Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med. 1990 Mar 15. 112(6):434-44. [Medline].

  24. Carroll T, Raff H, Findling JW. Late-night salivary cortisol for the diagnosis of Cushing syndrome: a meta-analysis. Endocr Pract. 2009 Jul-Aug. 15(4):335-42. [Medline].

  25. Kidambi S, Raff H, Findling JW. Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome. Eur J Endocrinol. 2007 Dec. 157(6):725-31. [Medline].

  26. Raff H. Utility of salivary cortisol measurements in Cushing's syndrome and adrenal insufficiency. J Clin Endocrinol Metab. 2009 Jul 14. [Medline].

  27. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992 Mar 4. 267(9):1244-52. [Medline].

  28. Corcept Therapeutics Incorporated announces FDA approval of Korlym (mifepristone) 300 mg tablets: First and only approved medication for Cushing’s Syndrome Patients. Corcept Therapeutics. Available at Accessed: February 21, 2012.

  29. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol. 2007 Nov. 157(5):561-9. [Medline].

  30. Nieman L, Cutler GB Jr. Cushing's syndrome. In: Degroot LJ, Besser M, Burger HG, et al, eds. Endocrinology. 3rd ed. Philadelphia, Pa: WB Saunders; 1995. 1741-69.

  31. Pavlatos FC, Smilo RP, Forsham PH. A rapid screening test for Cushing's syndrome. JAMA. 1965 Aug 30. 193:720-3. [Medline].

  32. Plotz CM, Knowlton AI, Ragan C. The natural history of Cushing's syndrome. Am J Med. 1952 Nov. 13(5):597-614. [Medline].

  33. Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing syndrome. Ann Intern Med. 2003 Jun 17. 138(12):980-91. [Medline].

  34. Yanovski JA, Cutler GB Jr. Glucocorticoid action and the clinical features of Cushing's syndrome. Endocrinol Metab Clin North Am. 1994 Sep. 23(3):487-509. [Medline].

Physical findings in Cushing syndrome.
Diagnosis of Cushing syndrome.
Table 1. Glucocorticoid Equivalencies[5]
TypeDrugDoseRelative Glucocorticoid PotencyRelative Mineralocorticoid PotencyPlasma Half-Life


Biologic Half-Life


Desoxycorticosterone acetate002070
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.